Status:
COMPLETED
Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Obesity
Healthy
Eligibility:
MALE
18-40 years
Phase:
NA
Brief Summary
The overall purpose of this explorative yet quantitative study project is to understand how blocking IL-6 signaling leads to the expansion of adipose tissue mass in humans in vivo. The aim is to gain ...
Detailed Description
Lacking IL-6 signaling leads to an expansion of adipose tissue mass in rodents and humans. However, the underlying mechanisms have not been identified.This project aims to investigate the overall hypo...
Eligibility Criteria
Inclusion
- Healthy males:
- Age ≥ 18 years and ≤ 40 years
- BMI \< 18 and \> 25 kg/m2
- Healthy (based on screening)
- Stable body weight for 6 months
- Obese males:
- Age ≥ 18 years and ≤ 40 years
- BMI ≥ 30 and ≤ 40 kg/m2
- Healthy (based on screening)
- Stable body weight for 6 months
Exclusion
- Smoking
- Evidence of severe thyroid or heart disease, inflammatory diseases, current infection, liver disease (transaminases \>2x upper normal range), kidney disease (creatinine \>1.5 mg/dl), known immunosuppressive disease, corticosteroid use, regular NSAID or paracetamol usage, aspirin use \>100 mg/d, history of carcinoma, history of tuberculosis, anemia (hematocrit \<33%), WBC \<2 x 10\^3/ul, platelets \<100 x 10\^3/ul, bleeding disorders, obstructive pulmonary disease
- Femoral hernia, vascular prosthesis, vascular thrombosis
- Previous nerve damage, many previous femoral catheter installations
Key Trial Info
Start Date :
April 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04687540
Start Date
April 9 2021
End Date
August 1 2021
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet, Centre of Inflammation and Metabolism (CIM) Centre for Physical Activity Research (CFAS)
Copenhagen, Denmark, 2100